...because it's in play.
A possible trade sale to Sanofi or Shire has been raised in "confidential" talks. Obviously Goldman Sachs want as many potential bidders to know about the unsolicited approach.
The shares have risen 28% in response.
There seems to be a little excitement/cash in the biotech/pharma market at the moment. Or is that just my wishful thinking?
Meanwhile DS are having problems with its Indian generic company Ranbaxy, who keep running foul of FDA on its manufacturing standards.
Not like the nice clean factory BOTA has.
No comments:
Post a Comment